Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 74 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who are clinically diagnosed as having stage Ta, T1, histological grade G1, G2 urothelial carcinoma of the bladder
Patients who are confirmed to be urinary cytology negative (class I, class II) within 4 weeks prior to the present TURBT.
P.S : 0-2 according to the ECOG.
Patients with a primary and solitary tumor.
CIS lesions in the bladder or a history thereof.
Grade 3 disease or a history thereof.
Patients experiencing recurrence within 3 months following TURBT for prior NMIBC.
Patients having stage T1 and high-grade disease.
Invasive cancer of T2 or greater, with definite lymph node or other organ metastasis, or a history thereof.
Patients who received intravesical chemotherapy/immunotherapy treatment within 6 months prior to the present TURBT.
Patients who underwent systemic chemotherapy or radiotherapy whose field of exposure included the bladder.
Patients with suspected bladder perforation at the time of the present TURBT.
A complication of a malignant tumor of the upper urinary tract or urethra, or a history thereof.
Malignancy within 5 years other than NMIBC (except thyroid cancer)
A serious viral or bacterial infection within the last 4 weeks.